KUKJEON PHARMACEUTICAL Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	134,441	121,998	103,711	85,354
Other Revenue	-	-	-	-0
Revenue	134,441	121,998	103,711	85,354
Revenue Growth (YoY)	15.22%	17.63%	21.51%	-
Cost of Revenue	111,949	96,721	84,195	67,409
Gross Profit	22,492	25,277	19,515	17,946
Selling, General & Admin	14,675	12,817	11,451	8,699
Research & Development	4,434	4,821	3,981	2,651
Operating Expenses	20,537	18,768	16,027	11,836
Operating Income	1,955	6,509	3,488	6,109
Interest Expense	-8,002	-5,735	-1,802	-284.47
Interest & Investment Income	960.79	1,591	1,037	208.91
Earnings From Equity Investments	-50.44	1.15	301.09	-
Currency Exchange Gain (Loss)	103.64	-253.67	-1,215	-869.65
Other Non Operating Income (Expenses)	9,317	-391.28	9,279	196.4
EBT Excluding Unusual Items	4,284	1,722	11,089	5,360
Gain (Loss) on Sale of Investments	1,272	16.28	67.84	-275.98
Gain (Loss) on Sale of Assets	-8.36	-	-69.18	-0
Pretax Income	4,342	1,738	11,088	5,084
Income Tax Expense	-1,293	-2,954	2,210	1,046
Earnings From Continuing Operations	5,636	4,692	8,877	4,038
Minority Interest in Earnings	956	132	70.7	-
Net Income	6,592	4,824	8,948	4,038
Net Income to Common	6,592	4,824	8,948	4,038
Net Income Growth	-30.58%	-46.09%	121.59%	-
Shares Outstanding (Basic)	49	49	49	44
Shares Outstanding (Diluted)	49	49	51	44
Shares Change (YoY)	-4.23%	-4.23%	16.16%	-
EPS (Basic)	134.33	98.31	182.35	91.54
EPS (Diluted)	134.02	98.00	11.35	91.00
EPS Growth	507.99%	763.36%	-87.53%	-
Free Cash Flow	3,086	-44,269	-29,304	-7,367
Free Cash Flow Per Share	62.89	-902.17	-571.94	-167.01
Dividend Per Share	10.000	10.000	-	-
Gross Margin	16.73%	20.72%	18.82%	21.02%
Operating Margin	1.45%	5.33%	3.36%	7.16%
Profit Margin	4.90%	3.95%	8.63%	4.73%
Free Cash Flow Margin	2.30%	-36.29%	-28.26%	-8.63%
EBITDA	6,851	9,643	4,932	7,215
EBITDA Margin	5.10%	7.90%	4.75%	8.45%
D&A For EBITDA	4,896	3,134	1,444	1,106
EBIT	1,955	6,509	3,488	6,109
EBIT Margin	1.45%	5.33%	3.36%	7.16%
Effective Tax Rate	-	-	19.94%	20.58%

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.